A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)

NCT03361501 | Completed Phase 3 FDA Drug

• 1 other identifier: ACA-CAP-002
• Study Type: interventional
• Target: 278
• Locations: 3 countries
• Sites: 68

Brief Summary

The primary objective of this study is to determine the efficacy of CaPre 4 g daily, compared to placebo, in lowering fasting TG levels in subjects with fasting TG levels ≥500 mg/dL and ≤1500 mg/dL (≥5.7 mmol/L and ≤17.0 mmol/L) after 12 weeks of treatment. Approximately 615 subjects will be screened to obtain 245 randomized subjects following a treatment allocation ratio of 2.5:1 (CaPre:placebo).

Conditions

Hypertriglyceridemia

Keywords

Omega-3 Fatty acids; Triglycerides

Outcome Measures

Primary Outcomes (1)

• Percent change in fasting TG levels from baseline (average of Week -2, -1, and 0) to Week 12 (average of Week 11 and 12) in patients with fasting TG levels ≥500 mg/dL and ≤1500 mg/dL (≥5.7 mmol/L and ≤17.0 mmol/L).

  Week 12

Secondary Outcomes (4)

• Percent change from baseline (average of Week -2, -1, and 0) to Week 12 (average of Week 11 and 12) in non-HDL-C.

  Week 12

• Percent change from baseline (Week -1 and 0) to Week 12 (average of Week 11 and 12) in VLDL-C (β-quantification).

  Week 12

• Percent change from baseline (average of Week -2, -1, and 0) to Week 12 (average of Week 11 and 12) in HDL-C.

  Week 12

• Percent change from baseline (average of Week -1 and 0) to Week 12 (average of Week 11 and 12) in LDL-C (β-quantification).

  Week 12

Other Outcomes (22)

• Percent change from baseline (average of Week -2, -1, and 0) to all measured visits other than Week 12 (Week 4, Week 18 and Week 26) in TG (persistence of the effect of CaPre on TG).

  Week 4; Week 18; Week 26

• Proportion of subjects with a fasting TG level below 500 mg/dL (<5.7 mmol/L) at Week 12 and at Week 26.

  Week 12; Week 26

• Percent change from baseline (average of Week -2, -1, and 0) to Week 12 (average of Week 11 and Week 12) and Week 26 in TC.

  Week 12; Week 26

Study Arms (2)

CaPre

EXPERIMENTAL

Drug: CaPre

Placebo

PLACEBO COMPARATOR

Drug: Placebo

Interventions

CaPre DRUG

4 x 1 g capsules administered orally once daily for 26 weeks

CaPre

Placebo DRUG

4 x 1 g capsules administered orally once daily for 26 weeks

Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects ≥18 years of age.
• Isolated hypertriglyceridemia, with triglycerides ≥500 mg/dL and \<1500 mg/dL (≥5.7 mmol/L and \<17.0 mmol/L) OR Mixed hyperlipidemia, with serum triglycerides ≥500 and \<1500 mg/dL treated with a statin, CAI or PCSK9I inhibitor, alone or in combination, that has been stable for 6 weeks prior to randomization. If the subject is not being treated and not contraindicated, a statin and/or CAI treatment may be initiated at the discretion of the Investigator at time of screening.
• Willingness to maintain current physical activity level and follow the NCEP-TLC diet throughout the study.
• Be informed of the nature of the study and give written consent prior to any study procedure.

You may not qualify if:

• Allergy or intolerance to OM3 fatty acids, OM3-acid ethyl esters, OM3 phospholipids, fish, shell fish, or any component of the study medication.
• Known lipoprotein lipase impairment or deficiency, or apo CII deficiency.
• Subjects with lysosomal acid lipase deficiency.
• Body mass index greater than 45 kg/m2.
• Subjects who are pregnant, lactating, and subjects of childbearing potential who are either planning to become pregnant or who are not using acceptable birth control methods during study participation. Subjects of childbearing potential are subjects who have experienced menarche and do not otherwise meet the criteria for subjects not of childbearing potential, defined as:
• Subjects who have had surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation); or
• Subjects who are postmenopausal, i.e., who have had a cessation of menses for at least 12 months without an alternative medical cause. A follicle stimulating hormone (FSH) test ≥40 mIU/mL may be used to confirm the post-menopausal state in women not using hormonal contraception or hormonal replacement therapy.
• Subjects of childbearing potential must test negative for pregnancy at the time of enrollment and agree to use an acceptable contraceptive method or remain abstinent during the study or for at least 8 weeks following the last dose of study medication, whichever is longer.
• Subjects taking tamoxifen, estrogens, or progestins, or other medications or nutritional supplements with mechanisms modifying estrogen or progestogen pathways, who have had dosage changes within 4 weeks prior to Visit 1.
• Use of oral or injected corticosteroids or anabolic steroids within 6 weeks prior to randomization.
• History of pancreatitis within the last 6 months prior to Visit 1.
• History of symptomatic gallstone disease within the last 5 years, unless treated with cholecystectomy.
• Diabetics requiring changes in medical therapy (other than short acting insulin dosage adjustments) within 6 weeks prior to Visit 1 or who have HbA1c greater than 9.5% at Visit 1.
• Clinical or biochemical evidence of hyperthyroidism not stable with medication for at least 6 weeks prior to Visit 1
• Uncontrolled hypothyroidism or thyroid stimulating hormone (TSH) level more than 1.5 × upper limit of normal (ULN).

Sponsors & Collaborators

• Grace Therapeutics Inc.: lead

Study Sites (68)

Research site

Birmingham, Alabama, 35216, United States

Location

Research site

Childersburg, Alabama, 35044, United States

Location

Research site

Encino, California, 91436, United States

Location

Research site

Long Beach, California, 90806, United States

Location

Research site

San Diego, California, 92111, United States

Location

Research site

Thousand Oaks, California, 91360, United States

Location

Research site

Torrance, California, 90503, United States

Location

Research site

Monument, Colorado, 80132, United States

Location

Research site

Clearwater, Florida, 33756, United States

Location

Research site

Coral Gables, Florida, 33134, United States

Location

Research site

DeLand, Florida, 32720, United States

Location

Research site

Fort Lauderdale, Florida, 33308, United States

Location

Research site

Jacksonville, Florida, 32205, United States

Location

Research site

Jacksonville, Florida, 32277, United States

Location

Research site

Miami, Florida, 33133, United States

Location

Research site

Miami, Florida, 33134, United States

Location

Research site

Miami, Florida, 33144, United States

Location

Research site

Miami Lakes, Florida, 33016, United States

Location

Research site

Dunwoody, Georgia, 30338, United States

Location

Research site

Peachtree Corners, Georgia, 30071, United States

Location

Research site

Savannah, Georgia, 31406, United States

Location

Research site

Boise, Idaho, 83712, United States

Location

Research site

Wauconda, Illinois, 60084, United States

Location

Research site

Iowa City, Iowa, 52242, United States

Location

Research site

Overland Park, Kansas, 66210, United States

Location

Research site

Biddeford, Maine, 04005, United States

Location

Research site

Baltimore, Maryland, 21229, United States

Location

Research site

Hyattsville, Maryland, 20782, United States

Location

Research site

Flint, Michigan, 48503, United States

Location

Research site

Tupelo, Mississippi, 38801, United States

Location

Research site

Norfolk, Nebraska, 68701, United States

Location

Research site

Las Vegas, Nevada, 89120, United States

Location

Research site

Las Vegas, Nevada, 89169, United States

Location

Research site

Albany, New York, 12206, United States

Location

Research site

Laurelton, New York, 11413, United States

Location

Research site

New Windsor, New York, 12553, United States

Location

Research site

New York, New York, 10036, United States

Location

Research site

The Bronx, New York, 10468, United States

Location

Research site

Morganton, North Carolina, 28655, United States

Location

Research site

Marion, Ohio, 43302, United States

Location

Research site

Oklahoma City, Oklahoma, 73112, United States

Location

Research site

Lansdale, Pennsylvania, 19446, United States

Location

Research site

Gaffney, South Carolina, 29340, United States

Location

Research site

Summerville, South Carolina, 29485, United States

Location

Research site

Union, South Carolina, 29379, United States

Location

Research site

Georgetown, Texas, 78626, United States

Location

Research site

Houston, Texas, 77043, United States

Location

Research site

Houston, Texas, 77074, United States

Location

Research site

Houston, Texas, 77079, United States

Location

Research site

Kerrville, Texas, 78028, United States

Location

Research site

Clinton, Utah, 84015, United States

Location

Research site

Ogden, Utah, 84405, United States

Location

Research site

Manassas, Virginia, 20110, United States

Location

Research site

Winnipeg, Manitoba, R2V4W3, Canada

Location

Research site

Halifax, Nova Scotia, B3H2Y9, Canada

Location

Research site

Brampton, Ontario, L6T0G1, Canada

Location

Research site

Burlington, Ontario, L7R1A4, Canada

Location

Research site

London, Ontario, N5W6A2, Canada

Location

Research site

Newmarket, Ontario, L3Y5G8, Canada

Location

Research site

Sarnia, Ontario, N7T4X3, Canada

Location

Research site

Québec, Quebec, G1N4V3, Canada

Location

Research site

Sherbrooke, Quebec, J1L0H8, Canada

Location

Research site

Mexico City, Mexico City, 06700, Mexico

Location

Research site

Culiacán, Sinaloa, 80230, Mexico

Location

Research site

Aguascalientes, 20230, Mexico

Location

Research site

Chihuahua City, 31203, Mexico

Location

Research site

Mexico City, 03300, Mexico

Location

Research site

Mexico City, 06760, Mexico

Location

Related Publications (1)

• Mozaffarian D, Maki KC, Bays HE, Aguilera F, Gould G, Hegele RA, Moriarty PM, Robinson JG, Shi P, Tur JF, Lapointe JF, Aziz S, Lemieux P; TRILOGY (Study of CaPre in Lowering Very High Triglycerides) investigators. Effectiveness of a Novel omega-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial. JAMA Netw Open. 2022 Jan 4;5(1):e2141898. doi: 10.1001/jamanetworkopen.2021.41898.

  PMID: 34989797 DERIVED

MeSH Terms

Conditions

Hypertriglyceridemia

Condition Hierarchy (Ancestors)

Hyperlipidemias; Dyslipidemias; Lipid Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• Dariush Mozaffarian, MD, DrPH

  Tufts Friedman School of Nutrition Science and Policy

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 21, 2017
• First Posted: December 5, 2017
• Study Start: February 1, 2018
• Primary Completion: September 24, 2019
• Study Completion: January 9, 2020
• Last Updated: August 12, 2020

Record last verified: 2020-08

Data Sharing

• IPD Sharing: Will not share

Locations

US (53); CA (9); ME (6)